Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$12.91 USD
+0.06 (0.47%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.92 +0.01 (0.08%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About Dividend Yield (TTM)
Stoke Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
STOK 12.91 +0.06(0.47%)
Will STOK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for STOK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STOK
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet
STOK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
Other News for STOK
D.R. Horton, IQVIA Holdings, Northrop Grumman And Other Big Stocks Moving Higher On Tuesday
12 Health Care Stocks Moving In Tuesday's After-Market Session
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Stoke Therapeutics (STOK) Initiates Coverage with Buy Rating from Jefferies | STOK Stock News
Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating | STOK Stock News